Skip to main content
Erschienen in: Pediatric Nephrology 4/2005

01.04.2005 | Original Article

High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse

verfasst von: Sevcan A. Bakkaloglu, Oguz Soylemezoglu, Necla Buyan, Tohru Funahashi, Atilla H. Elhan, Harun Peru, Kibriya Fidan, Sebahat Yılmaz, Enver Hasanoglu

Erschienen in: Pediatric Nephrology | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Adiponectin (ADPN), exclusively expressed and secreted from adipocytes, is a recently discovered protein hormone with anti-atherogenic and anti-inflammatory properties in contrast to other well-known adipocytokines. It has independent negative associations with obesity and hyperinsulinemia/insulin resistance. Apart from chronic renal failure, nephrotic syndrome was suggested as the only renal disease condition associated with raised plasma ADPN levels in adults. We aimed to evaluate the effect of nephrotic state on serum adiponectin (ADPN) levels in pediatric patients with steroid-responsive nephrotic syndrome (SRNS) by comparing the levels in relapse and remission as well as in control subjects and documenting possible relationships between ADPN and proteinuria as well as serum protein/lipid parameters. 34 patients with SRNS and 22 healthy age, sex and BMI-matched control subjects were enrolled into the study. 15 of the 34 SRNS patients had active diseases, and these were known as the SRNS-relapse group (ten relapsed and five newly-diagnosed patients), while the remaining 19 were in complete remission (the SRNS-remission group). Serum ADPN levels, blood chemistry (protein/albumin, triglyceride (TG), cholesterol (Cho) and lipoprotein levels) and 24-hour proteinuria were studied. ADPN levels were determined by ELISA. As expectedly, there were significant alterations in serum protein-lipid parameters and 24-hour proteinuria levels in SRNS patients consistent with their disease activity. SRNS-relapse patients had substantially higher ADPN levels (36.77±15.06 (5.61–59.41, median 39.84) μg/ml), compared to those in SRNS-remission and control groups (14.17±6.02 (3.28–29.40, median 12.80) μg/ml and 11.84±7.53 (2.81–31.46, median 10.85) μg/ml, respectively, p=0.001). There were strong positive correlations between serum ADPN levels and Cho (r=0.637, p=0.000), TG (r=0.516, p=0.002), low density lipoprotein (r=0.614, p=0.000) levels and 24-hour proteinuria (r=0.828, p=0.000) levels, whereas protein (r=−0.695, p=0.000) and albumin (r=0.732, p=0.000) levels were inversely correlated with ADPN levels. Regression analysis showed a significant correlation between ADPN and proteinuria (p=0.000). In conclusion, remarkably increased serum ADPN levels were detected in SRNS-relapse compared to those in SRNS-remission. This phenomenon might be the reflection of a compensatory response to nephrotic state characterized by massive proteinuria, hypoalbuminemia and hyperlipidemia.
Literatur
1.
Zurück zum Zitat Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Bioph Res Co 221:286–289CrossRef Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Bioph Res Co 221:286–289CrossRef
2.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476 Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476
3.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through cAMP-dependent pathway. Circulation 102:1296–1301 Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through cAMP-dependent pathway. Circulation 102:1296–1301
4.
Zurück zum Zitat Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMed Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMed
5.
Zurück zum Zitat Trayhurn B, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. P Nutr Soc 60:329–339 Trayhurn B, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. P Nutr Soc 60:329–339
6.
Zurück zum Zitat Auwerx J, Bouiloon R, Collen D, Geboers J (1988) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68–72 Auwerx J, Bouiloon R, Collen D, Geboers J (1988) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68–72
7.
Zurück zum Zitat Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Bioph Res Co 257:79–83CrossRef Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Bioph Res Co 257:79–83CrossRef
8.
Zurück zum Zitat Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscl Throm Vas 20:1595–1599 Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscl Throm Vas 20:1595–1599
9.
Zurück zum Zitat Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocr Metab 86:1930–1935CrossRef Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocr Metab 86:1930–1935CrossRef
10.
Zurück zum Zitat Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA (2002) Plasma adiponectin concentrations in children: Relationships with obesity and insulinemia. J Clin Endocr Metab 87:4652–4656CrossRef Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA (2002) Plasma adiponectin concentrations in children: Relationships with obesity and insulinemia. J Clin Endocr Metab 87:4652–4656CrossRef
11.
Zurück zum Zitat Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–41 Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–41
12.
Zurück zum Zitat Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2003) Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 84:S98–102CrossRef Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2003) Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 84:S98–102CrossRef
13.
Zurück zum Zitat Ozata M, Oktenli C, Gulec M, Ozgurtas T, Bulucu F, Caglar K, Bingol N, Vural A, Ozdemir IC (2002) Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocr Metab 87:853–8CrossRef Ozata M, Oktenli C, Gulec M, Ozgurtas T, Bulucu F, Caglar K, Bingol N, Vural A, Ozdemir IC (2002) Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocr Metab 87:853–8CrossRef
14.
Zurück zum Zitat Buyan N, Ozkaya O, Bideci A, Soylemezoglu O, Cinaz P, Gonen S, Kalman S, Bakkaloglu S, Hasanoglu E (2003) Leptin, soluble leptin receptor, and transforming growth factor-beta1 levels in minimal change nephrotic syndrome. Pediatr Nephrol 18:1009–1014 Buyan N, Ozkaya O, Bideci A, Soylemezoglu O, Cinaz P, Gonen S, Kalman S, Bakkaloglu S, Hasanoglu E (2003) Leptin, soluble leptin receptor, and transforming growth factor-beta1 levels in minimal change nephrotic syndrome. Pediatr Nephrol 18:1009–1014
15.
Zurück zum Zitat Schroth M, Kratzsch J, Groschl M, Rauh M, Rascher W, Dotsch J (2003) Increased soluble leptin receptor in children with nephrotic syndrome. J Clin Endocr Metab 88:5497–501CrossRef Schroth M, Kratzsch J, Groschl M, Rauh M, Rascher W, Dotsch J (2003) Increased soluble leptin receptor in children with nephrotic syndrome. J Clin Endocr Metab 88:5497–501CrossRef
16.
Zurück zum Zitat International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159–165PubMed International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159–165PubMed
17.
Zurück zum Zitat International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564PubMed International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564PubMed
18.
Zurück zum Zitat Clarck AG, Barratt TM (1999) Steroid responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams & Wilkins, Baltimore, MD, pp 731–747 Clarck AG, Barratt TM (1999) Steroid responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams & Wilkins, Baltimore, MD, pp 731–747
19.
Zurück zum Zitat Hoyer PF, Honda S, Barthels M, Krohin HP, Brodehl J (1986) Thromboembolic complications in children with nephrotic syndrome. Acta Pediatr Scand 75:804–810 Hoyer PF, Honda S, Barthels M, Krohin HP, Brodehl J (1986) Thromboembolic complications in children with nephrotic syndrome. Acta Pediatr Scand 75:804–810
20.
Zurück zum Zitat Zimmerman RL, Novek S, Chen JT, Roggli V (1994) Pulmonary thrombosis in a 10-year-old child with minimal change disease and nephrotic syndrome. A clinical, radiologic, and pathologic correlation with literature review. Am J Clin Pathol 101:230–236PubMed Zimmerman RL, Novek S, Chen JT, Roggli V (1994) Pulmonary thrombosis in a 10-year-old child with minimal change disease and nephrotic syndrome. A clinical, radiologic, and pathologic correlation with literature review. Am J Clin Pathol 101:230–236PubMed
21.
Zurück zum Zitat Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J (1984) Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 104:61–64 Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J (1984) Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 104:61–64
22.
Zurück zum Zitat Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, Kakei M, Fujishima H, Ito S (2004) Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Bioph Res Co 316:165–169CrossRef Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, Kakei M, Fujishima H, Ito S (2004) Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Bioph Res Co 316:165–169CrossRef
23.
Zurück zum Zitat Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed
Metadaten
Titel
High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse
verfasst von
Sevcan A. Bakkaloglu
Oguz Soylemezoglu
Necla Buyan
Tohru Funahashi
Atilla H. Elhan
Harun Peru
Kibriya Fidan
Sebahat Yılmaz
Enver Hasanoglu
Publikationsdatum
01.04.2005
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 4/2005
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-004-1770-z

Weitere Artikel der Ausgabe 4/2005

Pediatric Nephrology 4/2005 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.